- ~20% patients diagnosed with HR+, HER2- early breast cancer (EBC) may experience disease recurrence/distant relapse in the first 10 years
- Risk of recurrence is higher for those with high risk clinical and/or pathological features, especially during the first few years on adjuvant endocrine therapy (ET)
- Novel treatments are needed to prevent early recurrences and distant metastases
Is there a place in Early Breast Cancer for a CDK4 & 6 inhibitor currently approved for HR+, HER2- advanced breast cancer in combination with ET ?
Abemaciclib combined with ET showed a statistically significant improvement in IDFS in patients with high risk HR+, HER2- EBC
Results indicate the prevention of early recurrence and a reduction in the risk of distant recurrence (metastatic disease) by a clinically meaningful 28.3%
Safety was consistent with the known profile of abemaciclib